12:00 AM
 | 
Nov 24, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TT-232: Phase II started

Thallion began the open-label, North American Phase II trial (TLN-232-202) in up to 49 patients who failed 1 prior therapy. Patients will receive 0.5,...

Read the full 97 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >